Globus Medical (GMED): Director sold ~$202K
Leslie V Norwalk, Director at Globus Medical, sold ~$202K of Globus Medical shares.
- ~$202K
- Approx. value · 2,000 sh @ $101.10
- 10K
- Holds after · shares reported
- Traded
- Jan 8, 2026
- Filed
- Jan 12, 2026
What stands out in this filing
- The sale was 16.1% of the shares this insider held before it; the filing reports 10,419 shares afterwards.
- 2,000 shares at an average of $101.10 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Oct 16, 2025Federal contract · $25K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $25K obligated to date
- Nov 7, 2025InsiderDirector sold ~$648K of GMED shares in the open market
- Nov 10, 2025InsiderDirector sold ~$170K of GMED shares in the open market
- Nov 11, 2025InsiderDirector sold ~$2.11M of GMED shares in the open market
- Nov 12, 2025InsiderDirector sold ~$2.15M of GMED shares in the open market
- Nov 25, 2025InsiderOfficer sold ~$675K of GMED shares in the open market
- Dec 12, 2025InsiderDirector sold ~$355K of GMED shares in the open market
- Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
- Jan 8, 2026 · this disclosureInsiderDirector sold ~$202K of GMED shares in the open market
What came next
- Jan 8, 2026InsiderCFO sold ~$363K of GMED shares in the open market
- Jan 13, 2026Federal contract · $42K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $42K obligated to date
- Jan 15, 2026Federal contract · $61K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $61K obligated to date
- Jan 22, 2026Federal contract · $27K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $27K obligated to date
- Jan 28, 2026Federal contract · $31K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $31K obligated to date
- Feb 12, 2026InsiderOfficer sold ~$877K of GMED shares in the open market
- Feb 20, 2026Federal contract · $64K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $64K obligated to date
- Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 25, 2026Insider · Their largest sale since 2019Officer sold ~$1.89M of GMED shares in the open market
- Feb 26, 2026Federal contract · $23K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $23K obligated to date
- Mar 3, 2026CongressDisclosed purchase of GMED — reported range $1,001 - $15,000
- Mar 10, 2026Federal contract · $23K obligatedDepartment of Defense awarded GLOBUS MEDICAL INC: $23K obligated to date
- Mar 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 23, 2026, John A. DeFord, Ph.D., a member of the Board of Directors (the “Board”) of Globus Medical, Inc. (the “Company”), informed the Company of his resignation from the Board effective immediately.”
- May 7, 2026Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Globus Medical
For Globus Medical, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GMED page.
Other recent filings by Leslie V Norwalk, Director
The full history of Leslie V Norwalk, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Globus Medical (GMED) insider traded, and how much?
Leslie V Norwalk, Director at Globus Medical, sold ~$202K of Globus Medical shares. 2,000 shares at $101.10.
When did it happen, and when was it made public?
Traded: Jan 8, 2026. Filed: Jan 12, 2026. That is 4 days between the two dates.
What stands out in this filing?
The sale was 16.1% of the shares this insider held before it; the filing reports 10,419 shares afterwards. 2,000 shares at an average of $101.10 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Globus Medical recently?
For Globus Medical, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GMED page.
Does this mean GMED stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Globus Medical
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 10, 2026
- SEC Form 4Nov 5, 2026
- SEC Form 144Nov 4, 2026
Everything OQRO holds on this company is on its GMED page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
